DrugPatentWatch Database Preview
Rempex Pharms Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for REMPEX PHARMS, and when can generic versions of REMPEX PHARMS drugs launch?
REMPEX PHARMS has two approved drugs.
There are seven US patents protecting REMPEX PHARMS drugs.
There are sixty patent family members on REMPEX PHARMS drugs in twenty-four countries and thirteen supplementary protection certificates in seven countries.
Summary for Rempex Pharms
| International Patents: | 60 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Rempex Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 10,183,034 | Start Trial | Start Trial | ||||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 8,680,136 | Start Trial | Y | Y | Start Trial | ||
| Rempex Pharms | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | 9,084,802 | Start Trial | Start Trial | ||||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 10,561,675 | Start Trial | Start Trial | ||||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 10,172,874 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Rempex Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 347919 | Start Trial |
| Japan | 2013535502 | Start Trial |
| Mexico | 2012012993 | Start Trial |
| Colombia | 6680667 | Start Trial |
| Colombia | 6650346 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Rempex Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2603514 | 122019000026 | Germany | Start Trial | PRODUCT NAME: VABORBACTAM, UND/ODER EIN SALZ UND/ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/18/1334 20181120 |
| 2603514 | CA 2019 00015 | Denmark | Start Trial | PRODUCT NAME: EN KOMBINATION AF VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, OG MEROPENEM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, SAERLIGT MEROPENEM TRIHYDRAT; REG. NO/DATE: EU/1/18/1334 20181122 |
| 2603514 | 2019C/514 | Belgium | Start Trial | PRODUCT NAME: UNE COMBINAISON DE VABORBACTAM, ET / OU D'UN DE SES SELS ET / OU HYDRATES, ET DU MEROPENEME, ET / OU DE SON SEL ET / OU DE SON HYDRATE, EN PARTICULIER DU MEROPENEME TRIHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1334 20181122 |
| 2603514 | 300977 | Netherlands | Start Trial | PRODUCT NAME: EEN COMBINATIE VAN VABORBACTAM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN, EN MEROPENEM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN, IN HET BIJZONDER MEROPENEM TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/18/1334 20181122 |
| 2603514 | 19C1022 | France | Start Trial | PRODUCT NAME: VABORBACTAM, ET/OU UN SEL ET/OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/18/1334 20181122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
